{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:21:30Z","timestamp":1773454890930,"version":"3.50.1"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Testosterone replacement therapy (TRT) has been recommended for the treatment of primary and secondary hypogonadism. However, long-term implications of TRT have not been investigated extensively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>The aim of this analysis was to evaluate health outcomes and costs associated with life-long TRT in patients suffering from Klinefelter syndrome and late-onset hypogonadism (LOH).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A Markov model was developed to assess cost-effectiveness of testosterone undecanoate (TU) depot injection treatment compared with no treatment. Health outcomes and associated costs were modeled in monthly cycles per patient individually along a lifetime horizon. Modeled health outcomes included development of type 2 diabetes, depression, cardiovascular and cerebrovascular complications, and fractures. Analysis was performed for the Swedish health-care setting from health-care payer's and societal perspective. One-way sensitivity analyses evaluated the robustness of results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>The main outcome measures were quality-adjusted life-years (QALYs) and total cost in TU depot injection treatment and no treatment cohorts. In addition, outcomes were also expressed as incremental cost per QALY gained for TU depot injection therapy compared with no treatment (incremental cost-effectiveness ratio [ICER]).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>TU depot injection compared to no-treatment yielded a gain of 1.67 QALYs at an incremental cost of 28,176 EUR (37,192 USD) in the Klinefelter population. The ICER was 16,884 EUR (22,287 USD) per QALY gained. Outcomes in LOH population estimated benefits of TRT at 19,719 EUR (26,029 USD) per QALY gained. Results showed to be considerably robust when tested in sensitivity analyses. Variation of relative risk to develop type 2 diabetes had the highest impact on long-term outcomes in both patient groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This analysis suggests that lifelong TU depot injection therapy of patients with hypogonadism is a cost-effective treatment in Sweden. Hence, it can support clinicians in decision making when considering appropriate treatment strategies for patients with testosterone deficiency.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/jsm.12277","type":"journal-article","created":{"date-parts":[[2013,8,12]],"date-time":"2013-08-12T21:22:18Z","timestamp":1376342538000},"page":"262-272","source":"Crossref","is-referenced-by-count":17,"title":["Is Testosterone Replacement Therapy in Males with Hypogonadism Cost-Effective? An Analysis in Sweden"],"prefix":"10.1093","volume":"11","author":[{"given":"Stefan","family":"Arver","sequence":"first","affiliation":[{"name":"Center for Andrology and Sexual Medicine \u00a0 , Stockholm , Sweden"},{"name":"Karolinska University Hospital\/Huddinge \u00a0 , Stockholm , Sweden"},{"name":"Department of Medicine \u00a0 , Stockholm , Sweden"},{"name":"Karolinska Institutet \u00a0 , Stockholm , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ba","family":"Luong","sequence":"additional","affiliation":[{"name":"Bayer Pharma AG , Berlin , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anina","family":"Fraschke","sequence":"additional","affiliation":[{"name":"Bayer AB , Solna , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ola","family":"Ghatnekar","sequence":"additional","affiliation":[{"name":"Swedish Institute for Health Economics , Lund , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanja","family":"Stanisic","sequence":"additional","affiliation":[{"name":"Analytica LA-SER International Inc. , L\u00f6rrach , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry","family":"Gultyev","sequence":"additional","affiliation":[{"name":"Analytica LA-SER International Inc. , L\u00f6rrach , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Analytica LA-SER International Inc. , L\u00f6rrach , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,1,1]]},"reference":[{"key":"2024032602363771100_bib1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.4158\/EP.8.6.439","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients\u20142002 update","volume":"8","author":"AACE Hypogonadism Task Force","year":"2002","journal-title":"Endocr Pract"},{"key":"2024032602363771100_bib2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/humupd\/dmh035","article-title":"Testosterone replacement therapy: Current trends and future directions","volume":"10","author":"Nieschlag","year":"2004","journal-title":"Hum Reprod Update"},{"key":"2024032602363771100_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2164\/jandrol.108.006486","article-title":"Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations","volume":"30","author":"Wang","year":"2009","journal-title":"J Androl"},{"key":"2024032602363771100_bib4","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1210\/jc.2011-1137","article-title":"Clinical review: Endogenous testosterone and mortality in men: A systematic review and meta-analysis","volume":"96","author":"Araujo","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2024032602363771100_bib5","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1210\/jc.2009-2354","article-title":"Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline","volume":"95","author":"Bhasin","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2024032602363771100_bib6","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2605.2008.00951.x","article-title":"Hypogonadism, ED, metabolic syndrome and obesity: A pathological link supporting cardiovascular diseases","volume":"32","author":"Corona","year":"2009","journal-title":"Int J Androl"},{"key":"2024032602363771100_bib7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2605.2009.00965.x","article-title":"Following the common association between testosterone deficiency and diabetes mellitus, can testosterone be regarded as a new therapy for diabetes?","volume":"32","author":"Corona","year":"2009","journal-title":"Int J Androl"},{"key":"2024032602363771100_bib8","article-title":"Testosterone and metabolic syndrome: A meta-analysis study","volume-title":"J Sex Med","author":"Corona","year":"2010"},{"key":"2024032602363771100_bib9","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1365-2605.2010.01117.x","article-title":"Type 2 diabetes mellitus and testosterone: A meta-analysis study","volume":"34","author":"Corona","year":"2011","journal-title":"Int J Androl"},{"key":"2024032602363771100_bib10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1530\/EJE-11-0447","article-title":"Hypogonadism as a risk factor for cardiovascular mortality in men: A meta-analytic study","volume":"165","author":"Corona","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"2024032602363771100_bib11","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.2337\/db09-0031","article-title":"Prediction of metabolic syndrome by low serum testosterone levels in men: Results from the study of health in Pomerania","volume":"58","author":"Haring","year":"2009","journal-title":"Diabetes"},{"key":"2024032602363771100_bib12","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1210\/jc.2009-1796","article-title":"Characteristics of secondary, primary, and compensated hypogonadism in aging men: Evidence from the European Male Ageing Study","volume":"95","author":"Tajar","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2024032602363771100_bib13","article-title":"A Dictionary of Units of Measurement \u00a9 2000 by Russ Rowlett and the University of North Carolina at Chapel Hill","author":"Rowlett","year":"2012"},{"key":"2024032602363771100_bib14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2164\/jandrol.05047","article-title":"Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations","volume":"27","author":"Nieschlag","year":"2006","journal-title":"J Androl"},{"key":"2024032602363771100_bib15","article-title":"Testosteronbrist V\u00e5rdprogramoch behandlingsrekommendationer [Hypogonadism Treatment Guidelines]","author":"Swedish Society for Andrology","year":"2010"},{"key":"2024032602363771100_bib16","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1517\/14656566.2010.505920","article-title":"Testosterone undecanoate in the treatment of male hypogonadism","volume":"11","author":"Edelstein","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"2024032602363771100_bib17","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1210\/jc.2004-0897","article-title":"Intramuscular testosterone undecanoate: Pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism","volume":"89","author":"Schubert","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2024032602363771100_bib18","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1210\/jc.2003-032006","article-title":"Long-term testosterone gel (androgel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypoganadal men","volume":"89","author":"Wang","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2024032602363771100_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the economic evaluation of health care programs","author":"Drummond","year":"2005","edition":"3rd edition"},{"key":"2024032602363771100_bib20","article-title":"General guidelines for economic evaluations from the Pharmaceutical Benefits Board","author":"International Society for Pharmacoeconomic Outcomes and Research","year":"2003"},{"key":"2024032602363771100_bib21","article-title":"General Guidelines for Economic Evaluation [in Swedish]. Pharmaceutical Benefits Board Sweden","author":"Edling","year":"2010"},{"key":"2024032602363771100_bib22","first-page":"4500","article-title":"Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men","volume":"85","author":"Swerdloff","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2024032602363771100_bib23","first-page":"2839","article-title":"Transdermal testosterone gel improves sexual function, mood, muscle strengths, and body composition parameters in hypogonadal men","volume":"85","author":"Wang","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2024032602363771100_bib24","article-title":"NCT00220298. Open one-arm study to investigate safety and efficacy of intramuscular injections of 1000 mg testosterone undecanoate (TU) in hypogonadal men at variable intervals during a 136-week to 192-week treatment including pharmacokinetics of TU during steady state in a subgroup of 30 patients. Data on file","author":"Bayer Schering Pharma [a].","year":"2009"},{"key":"2024032602363771100_bib25","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1365-2265.2009.03744.x","article-title":"Randomized cross-over clinical trial of injectable vs. implantable depot testosterone for maintenance of testosterone replacement therapy in androgen deficient men","volume":"73","author":"Fennell","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024032602363771100_bib26","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.2337\/diacare.27.5.1036","article-title":"Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men","volume":"27","author":"Laaksonen","year":"2004","journal-title":"Diabetes Care"},{"key":"2024032602363771100_bib27","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/archpsyc.61.2.162","article-title":"Increased incidence of diagnosed depressive illness in hypogonadal older men","volume":"61","author":"Shores","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"2024032602363771100_bib28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4088\/JCP.v66n0102","article-title":"Low testosterone levels predict incident depressive illness in older men: Effects of age and medical morbidity","volume":"66","author":"Shores","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"2024032602363771100_bib29","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s00125-008-1156-z","article-title":"The Danish National Diabetes Register: Trends in incidence, prevalence and mortality","volume":"51","author":"Carstensen","year":"2008","journal-title":"Diabetologia"},{"key":"2024032602363771100_bib30","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.2337\/diacare.28.8.2013","article-title":"Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study","volume":"28","author":"Schmidt","year":"2005","journal-title":"Diabetes Care"},{"key":"2024032602363771100_bib31","doi-asserted-by":"crossref","first-page":"490","DOI":"10.2337\/diacare.23.4.490","article-title":"Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: Prospective results from the Massachusetts male aging study","volume":"23","author":"Stellato","year":"2000","journal-title":"Diabetes Care"},{"key":"2024032602363771100_bib32","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2337\/diacare.26.2.360","article-title":"The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region","volume":"26","author":"Woodward","year":"2003","journal-title":"Diabetes Care"},{"key":"2024032602363771100_bib33","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s00127-002-0566-3","article-title":"Gender and age-specific first incidence of DSM-III-R psychiatric disorders in the general population. Results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS)","volume":"37","author":"Bijl","year":"2002","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"2024032602363771100_bib34","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","article-title":"A meta-analysis of previous fracture and subsequent fracture risk","volume":"35","author":"Kanis","year":"2004","journal-title":"Bone"},{"key":"2024032602363771100_bib35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/bmj.38678.389583.7C","article-title":"Excess risk of fatal coronary heart disease associated with diabetes in men and women: Meta-analysis of 37 prospective cohort studies","volume":"332","author":"Huxley","year":"2006","journal-title":"BMJ"},{"key":"2024032602363771100_bib36","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/archinte.162.15.1737","article-title":"Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: A meta-analysis","volume":"162","author":"Kanaya","year":"2002","journal-title":"Arch Intern Med"},{"key":"2024032602363771100_bib37","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1023\/A:1013171831202","article-title":"Swedish population health-related quality of life results using the EQ-5D","volume":"10","author":"Burstr\u00f6m","year":"2001","journal-title":"Qual Life Res"},{"key":"2024032602363771100_bib38","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1007\/s00125-002-0858-x","article-title":"Revealing the cost of type II diabetes in Europe","volume":"45","author":"J\u00f6nsson","year":"2002","journal-title":"Diabetologia"},{"key":"2024032602363771100_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/02813430902808643","article-title":"Physical activity and quality of life in subjects with chronic disease: Chronic obstructive pulmonary disease compared with rheumatoid arthritis and diabetes mellitus","volume":"27","author":"Arne","year":"2009","journal-title":"Scand J Prim Health Care"},{"key":"2024032602363771100_bib40","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10198-006-0008-3","article-title":"Resource use and costs associated with patients treated for depression in primary care","volume":"8","author":"Sobocki","year":"2007","journal-title":"Eur J Health Econ"},{"key":"2024032602363771100_bib41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1524-4733.2006.00162.x","article-title":"Health-related quality of life measured with EQ-5D in patients treated for depression in primary care","volume":"10","author":"Sobocki","year":"2007","journal-title":"Value Health"},{"key":"2024032602363771100_bib42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-7525-5-21","article-title":"Which health-related quality of life score? A comparison of alternative utility measures in patients with type 2 diabetes in the ADVANCE trial","volume":"5","author":"Glasziou","year":"2007","journal-title":"Health Qual Life Outcomes"},{"key":"2024032602363771100_bib43","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/01.mlr.0000172050.67085.4f","article-title":"A national catalog of preference-based scores for chronic conditions in the United States","volume":"43","author":"Sullivan","year":"2005","journal-title":"Med Care"},{"key":"2024032602363771100_bib44","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/0272989X9701700403","article-title":"Incorporating future costs in medical cost-effectiveness analysis: Implications for the cost-effectiveness of the treatment of hypertension","volume":"17","author":"Johannesson","year":"1997","journal-title":"Med Decis Making"},{"key":"2024032602363771100_bib45","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2796.1999.00546.x","article-title":"Costs of coronary heart disease and stroke: The case of Sweden","volume":"246","author":"Zethraeus","year":"1999","journal-title":"J Intern Med"},{"key":"2024032602363771100_bib46","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1017\/S0266462304001217","article-title":"Cost of stroke in Sweden: An incidence estimate","volume":"20","author":"Ghatnekar","year":"2004","journal-title":"Int J Technol Assess Health Care"},{"key":"2024032602363771100_bib47","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/HJR.0b013e3282f37a22","article-title":"Utility loss and indirect costs after stroke in Sweden","volume":"15","author":"Lindgren","year":"2008","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"2024032602363771100_bib48","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/17453670710015094","article-title":"Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden","volume":"79","author":"Str\u00f6m","year":"2008","journal-title":"Acta Orthop"},{"key":"2024032602363771100_bib49","article-title":"Summary of Product Characteristics Nebido\u00ae [In Swedish]. FASS [The Swedish Medicines Information Engine]","author":"FASS","year":"2011"},{"key":"2024032602363771100_bib50","article-title":"The Swedish Medicines Information Engine. FASS","author":"FASS","year":"2010"},{"key":"2024032602363771100_bib51","article-title":"Statistics Sweden. SCB 2008","author":"FASS","year":"2009"},{"key":"2024032602363771100_bib52","article-title":"Consumption and production by age in Sweden: Basic facts and health economic implications. Stockholm","author":"Ekman","year":"2002"},{"key":"2024032602363771100_bib53","article-title":"Euro foreign exchange reference rates","author":"European Central Bank","year":"2011"},{"key":"2024032602363771100_bib54","article-title":"NCT00185198. Multicenter, double blind, randomized, placebo controlled study of Testogel\u00ae (testosterone 50\u2013100 mg) to evaluate its efficacy and safety in men presenting with typical symptoms of partial androgen deficiency of aging males (PADAM) over a period of 6 months with 12 months open label follow-up. Data on file","author":"Bayer Schering Pharma [b]","year":"2009"},{"key":"2024032602363771100_bib55","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/j.1939-4640.2003.tb02638.x","article-title":"Clinical and diagnostic features of patients with suspected Klinefelter syndrome","volume":"24","author":"Kamischke","year":"2003","journal-title":"J Androl"},{"key":"2024032602363771100_bib56","article-title":"WHO Global InfoBase: Sweden: All Data","author":"WHO Statistical Information System (WHOSIS)","year":"2010"},{"key":"2024032602363771100_bib57","article-title":"WHO Global InfoBase Diabetes: Sweden: All Data. WHO Statistical Information System (WHOSIS)","author":"WHO","year":"2010"},{"key":"2024032602363771100_bib58","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1210\/jc.2011-2513","article-title":"Characteristics of androgen deficiency in late-onset hypogonadism: Results from the European Male Aging Study (EMAS)","volume":"97","author":"Tajar","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2024032602363771100_bib59","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.beem.2010.07.002","article-title":"Testosterone, cardiovascular disease and the metabolic syndrome","volume":"25","author":"Corona","year":"2011","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2024032602363771100_bib60","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1111\/j.1743-6109.2012.02810.x","article-title":"The direct and indirect costs among U.S. privately insured employees with hypogonadism","volume":"9","author":"Kaltenboeck","year":"2012","journal-title":"J Sex Med"},{"key":"2024032602363771100_bib61","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1743-6109.2012.02944.x","article-title":"The 20-year public health impact and direct cost of testosterone deficiency in U.S. men","volume":"10","author":"Moskovic","year":"2013","journal-title":"J Sex Med"},{"key":"2024032602363771100_bib62","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/j.1743-6109.2007.00531.x","article-title":"The burden of testosterone deficiency syndrome in adult men: Economic and quality-of-life impact","volume":"4","author":"Maggi","year":"2007","journal-title":"J Sex Med"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515305609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515305609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/11\/1\/262\/48359825\/jsm_11_1_262.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/11\/1\/262\/48359825\/jsm_11_1_262.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T03:13:46Z","timestamp":1711422826000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/11\/1\/262\/6958339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,1]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,1,1]]},"published-print":{"date-parts":[[2014,1,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jsm.12277","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2014,1]]},"published":{"date-parts":[[2014,1,1]]}}}